Lundbeck
Alkermes Ups Bid for Avadel Amid Lundbeck’s Competing Offer in Narcolepsy Drug Takeover Battle
Alkermes; Avadel Pharmaceuticals; Lundbeck; bidding war; Lumryz; narcolepsy; acquisition; contingent value right; pharma M&A; idiopathic hypersomnia
Lundbeck Fires First Shot in Bidding War With Alkermes Over Sleep Biotech Avadel
Lundbeck; Alkermes; Avadel; bidding war; sleep biotech; Lumryz; idiopathic hypersomnia; FDA approval; deal; CVR
OpenAI Collaborates with Thermo Fisher and Lundbeck to Enhance Pharma Research
OpenAI; Thermo Fisher; Lundbeck; Pharma; AI Integration
FDA Rejects Lundbeck and Otsuka’s Rexulti for PTSD on Insufficient Efficacy Evidence
FDA; Rexulti; Lundbeck; Otsuka; PTSD; brexpiprazole; sertraline; Complete Response Letter; sNDA; clinical trials; drug approval
Lundbeck Offloads Assets to Three Partners as It Exits 27 Markets, Leaving 602 Jobless
Lundbeck; market exit; asset offloading; partnerships; job cuts; Swixx Group; Zuellig Pharma; NewBridge Pharmaceuticals; restructuring; neuro-rare diseases; neuro-specialty diseases
FDA Advisory Committee Rejects Lundbeck and Otsuka’s PTSD Bid for Rexulti
Lundbeck; Otsuka; Rexulti; FDA advisory committee; PTSD; brexpiprazole; sertraline; clinical trials; drug efficacy; setback
Lundbeck Strengthens Neuro-Rare Disease Portfolio with $2.6 Billion Acquisition of Longboard Pharmaceuticals
Lundbeck, Longboard Pharmaceuticals, Neuro-Rare Diseases, Acquisition, Biotech, Pharmaceutical Industry